retatrutide what is it clinical trial Retatrutide—A Game Changer in Obesity Pharmacotherapy Retatrutide Results: 28.3% Weight Loss
Description
Press release, December 11, 2025
12-14 Titers tended to be low at week 30 and did not predict response to therapy or incidence of side effects or other safety issues
Recent Findings Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized the treatment of diabetes and obesity and are increasingly being identified as promising therapies for a wide range of conditions
Figure 2: Receptor selectivity scatter
And, although pulmonary aspiration is a rare complication in patients undergoing anesthetic care, it is devastating
The weight loss data from this period is striking
